New quinoxaline 1, 4-di-N-oxides: anticancer and hypoxia-selective therapeutic agents

Area of Science:

• Medicinal Chemistry
• Organic Synthesis
• Cancer Biology

Background:

• Quinoxaline 1,4-di-N-oxides are a class of heterocyclic compounds with diverse biological activities.
• Developing novel anticancer agents with improved efficacy and selectivity is a critical area of research.
• Hypoxia-selective cytotoxins are particularly interesting for targeting solid tumors, which often contain hypoxic regions.

Purpose of the Study:

• To synthesize and evaluate a new series of quinoxaline 1,4-di-N-oxides for their antitumor and hypoxic-selective cytotoxic activities.
• To identify lead compounds with potent activity against specific cancer cell lines.
• To assess the selectivity of these compounds under hypoxic conditions.

Main Methods:

• Synthesis of novel quinoxaline 1,4-di-N-oxide derivatives.
• In vitro evaluation of antitumor activity against human liver carcinoma (Hepg2) and brain tumor (U251) cell lines.
• Assessment of hypoxic-selective cytotoxicity using Ehrlich Ascites Carcinoma (EAC) cell line and determining the hypoxia-to-normoxia ratio (HCR).

Main Results:

• Compounds 5b and 9b showed significant cytotoxic effects against Hepg2 cells with IC50 values of 0.77 and 0.50 microg/mL, respectively.
• No significant antitumor activity was observed against the U251 cell line for any of the tested compounds.
• Compound 4 exhibited the most potent hypoxia-selective cytotoxicity against EAC cells (IC50 2.5 microg/mL, potency 22 microg/mL, HCR>40), outperforming the standard compound.
• Compounds 8b and 9b also demonstrated greater selectivity than the standard.

Conclusions:

• The synthesized quinoxaline 1,4-di-N-oxide derivatives possess varying degrees of antitumor and hypoxia-selective cytotoxic activities.
• Compounds 5b and 9b are potential candidates for further investigation against liver cancer.
• Compound 4 is a highly promising hypoxia-selective cytotoxin, warranting further preclinical development for cancer therapy.
• The study highlights the potential of quinoxaline 1,4-di-N-oxides as a scaffold for developing novel anticancer agents, particularly those targeting hypoxic tumors.